Actively Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Led by Merck Sharp & Dohme LLC · Updated on 2026-05-08
270
Participants Needed
45
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
CONDITIONS
Official Title
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments
- If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART)
- If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
- If hepatitis C virus (HCV) infected, must have undetectable HCV viral load
You will not qualify if you...
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
- Has uncontrolled significant cardiovascular disease or cerebrovascular disease
- Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
- Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
- Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 2 years
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active infection requiring systemic therapy, with exceptions
- History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Has HBV or HCV infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 45 locations
1
The University of Alabama at Birmingham ( Site 1005)
Birmingham, Alabama, United States, 35249
Actively Recruiting
2
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003)
Miami, Florida, United States, 33136
Actively Recruiting
3
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009)
Hackensack, New Jersey, United States, 07601
Actively Recruiting
4
NEXT Oncology ( Site 1010)
Austin, Texas, United States, 78758
Actively Recruiting
5
NEXT Oncology ( Site 1011)
Houston, Texas, United States, 77054
Actively Recruiting
6
NEXT Oncology ( Site 1012)
Irving, Texas, United States, 75039
Actively Recruiting
7
Virginia Commonwealth University ( Site 1008)
Richmond, Virginia, United States, 23219
Actively Recruiting
8
Centro de Estudios Clínicos SAGA ( Site 0033)
Santiago, Region M. de Santiago, Chile, 7500653
Actively Recruiting
9
FALP ( Site 0031)
Santiago, Region M. de Santiago, Chile, 7500921
Actively Recruiting
10
Pontificia Universidad Catolica de Chile ( Site 0032)
Santiago, Region M. de Santiago, Chile, 8330032
Actively Recruiting
11
Bradford Hill Centro de Investigaciones Clinicas ( Site 0030)
Santiago, Region M. de Santiago, Chile, 8420383
Actively Recruiting
12
Peking University First Hospital ( Site 0180)
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
13
Chongqing Cancer Hospital ( Site 0186)
Chongqing, Chongqing Municipality, China, 400030
Actively Recruiting
14
Hunan Cancer Hospital ( Site 0181)
Changsha, Hunan, China, 410013
Actively Recruiting
15
The First Hospital of Jilin University ( Site 0185)
Changchun, Jilin, China, 130021
Actively Recruiting
16
West China Hospital Sichuan University ( Site 0187)
Chengdu, Sichuan, China, 610041
Actively Recruiting
17
Institut Paoli Calmettes ( Site 0053)
Marseille, Bouches-du-Rhone, France, 13273
Actively Recruiting
18
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 0054)
Rennes, Ille-et-Vilaine, France, 35000
Actively Recruiting
19
Centre Oscar Lambret ( Site 0051)
Lille, Nord, France, 59000
Actively Recruiting
20
Gustave Roussy ( Site 0050)
Villejuif, Val-de-Marne, France, 94800
Actively Recruiting
21
Rambam Health Care Campus ( Site 0082)
Haifa, Israel, 3109601
Actively Recruiting
22
Rabin Medical Center ( Site 0081)
Petah Tikva, Israel, 4941492
Actively Recruiting
23
Sheba Medical Center ( Site 0080)
Ramat Gan, Israel, 5265601
Actively Recruiting
24
National Cancer Center Hospital East ( Site 0190)
Kashiwa, Chiba, Japan, 277-8577
Actively Recruiting
25
Cancer Institute Hospital of JFCR ( Site 0192)
Koto, Tokyo, Japan, 135-8550
Actively Recruiting
26
Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 0191)
Osaka, Japan, 541-8567
Actively Recruiting
27
Radboudumc ( Site 0091)
Nijmegen, Gelderland, Netherlands, 6525 GA
Actively Recruiting
28
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0090)
Amsterdam, North Holland, Netherlands, 1066 CX
Actively Recruiting
29
Amsterdam UMC, locatie VUmc ( Site 0093)
Amsterdam, North Holland, Netherlands, 1081HV
Actively Recruiting
30
Erasmus Medisch Centrum ( Site 0092)
Rotterdam, South Holland, Netherlands, 3015 GD
Actively Recruiting
31
Seoul National University Hospital ( Site 0150)
Seoul, South Korea, 03080
Actively Recruiting
32
Severance Hospital Yonsei University Health System ( Site 0151)
Seoul, South Korea, 03722
Actively Recruiting
33
Asan Medical Center ( Site 0153)
Seoul, South Korea, 05505
Actively Recruiting
34
Samsung Medical Center ( Site 0152)
Seoul, South Korea, 06351
Actively Recruiting
35
Institut Català d'Oncologia - L'Hospitalet ( Site 0113)
L'Hospitalet de Llobregat, Barcelona, Spain, 08908
Actively Recruiting
36
HOSPITAL CLÍNIC DE BARCELONA ( Site 0112)
Barcelona, Catalonia, Spain, 08036
Actively Recruiting
37
Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0111)
Madrid, Madrid, Comunidad de, Spain, 28040
Actively Recruiting
38
Hospital Universitario Virgen de la Victoria ( Site 0114)
Málaga, Spain, 29016
Actively Recruiting
39
Chi Mei Medical Center ( Site 0162)
Tainan, Tainan, Taiwan, 71004
Actively Recruiting
40
National Cheng Kung University Hospital ( Site 0161)
Tainan, Taiwan, 704
Actively Recruiting
41
National Taiwan University Hospital ( Site 0160)
Taipei, Taiwan, 10002
Actively Recruiting
42
Ankara Bilkent Şehir Hastanesi. ( Site 0131)
Çankaya, Ankara, Turkey (Türkiye), 06800
Actively Recruiting
43
Ankara University Health Practice and Research Hospitals ( Site 0134)
Ankara, Turkey (Türkiye), 06620
Actively Recruiting
44
Hacettepe Universite Hastaneleri ( Site 0130)
Ankara, Turkey (Türkiye), 6230
Actively Recruiting
45
Koc University, School of Medicine ( Site 0133)
Istanbul, Turkey (Türkiye), 34010
Actively Recruiting
Research Team
T
Toll Free Number
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here